Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
RASSF1 encodes a protein similar to the RAS effector proteins. Additionally we are shipping Ras Association (RalGDS/AF-6) Domain Family Member 1 Proteins (6) and Ras Association (RalGDS/AF-6) Domain Family Member 1 Kits (3) and many more products for this protein.
Showing 10 out of 141 products:
Human Monoclonal RASSF1 Primary Antibody for EIA, IF - ABIN121164
Agathanggelou, Cooper, Latif: Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. in Cancer research 2005
Show all 4 references for ABIN121164
Human Monoclonal RASSF1 Primary Antibody for ICC, ELISA - ABIN165456
Dammann, Schagdarsurengin, Seidel, Strunnikova, Rastetter, Baier, Pfeifer: The tumor suppressor RASSF1A in human carcinogenesis: an update. in Histology and histopathology 2005
Show all 4 references for ABIN165456
Human Polyclonal RASSF1 Primary Antibody for IF (p), IHC (p) - ABIN673764
Liu, Ao, Zhou, Cui, Zhou, Yuan, Xiang, Cao, Liu: CpG island hypermethylation of multiple tumor suppressor genes associated with loss of their protein expression during rat lung carcinogenesis induced by 3-methylcholanthrene and diethylnitrosamine. in Biochemical and biophysical research communications 2010
Show all 2 references for ABIN673764
Mouse (Murine) Polyclonal RASSF1 Primary Antibody for ELISA, WB - ABIN190784
Yan, Venkataramu, Ibrahim, Liu, Shen, Diaz, Centeno, Weber, Leu, Shapiro, Eng, Yeatman, Huang: Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. in Clinical cancer research : an official journal of the American Association for Cancer Research 2006
The presence of higher RASSF1A methylation levels in fine-needle aspiration cytology specimens of nodular goitre may be useful in the assessment of oncological risk.
this meta-analysis demonstrated that RASSF1A promoter methylation is significantly associated with increased risk of renal cell cancer
Overexpression of RASSF1A downregulated the cyclin D1 (show CCND1 Antibodies).
Results show that RASSF1A is involved in colorectal tumorigenesis. Its promotor region is bind to miR (show MLXIP Antibodies)-181b stimulating its expression.
The meta-analysis suggested that there was a significant association between aberrant RASSF1A methylation and head and neck squamous cell carcinoma.
The present meta.analysis provides convincing evidence that the promoter methylation ratio of RASSF1A and p16 (show CDKN2A Antibodies) is associated with clinicopathological features in lung cancers, and could be used as effective biomarkers in early diagnosis in lung cancers.
Loss of RASSF1A is associated with gastric cancer.
Different genetic mechanisms seem to contribute to RASSF1 deregulation in this setting, but RASSF1 methylation does not seem to substantially affect RASSF1 isoforms expression.
RASSF1C gene is not involved in Clear-cell renal cell carcinoma (show MOK Antibodies) (ccRCC)progression and we propose that the measurements of RASSF1A mRNA levels in paired tumor-normal kidney tissue could serve as a new prognostic factor in ccRCC
Distinct RASSF1 isoforms have opposing functions, which provide a biomarker for YAP1 (show YAP1 Antibodies) activation and explain correlations of RASSF1 methylation with advanced invasive disease in humans.
essential role of RASSF1A in regulating TNF-alpha (show TNF Antibodies) signalling in cardiomyocytes, with RASSF1A being key in the formation of the TNFR (show TNFRSF1A Antibodies) complex and in signal transmission to the downstream targets
RASSF1A may function to interfere and restrict TLR-driven activation of NF-kappaB (show NFKB1 Antibodies) and is essential for protection against inflammation-induced injury.
nickel-smelting fumes upregulated the expression of RASSF1A. This suggest that nickel-smelting fumes could be toxic to cells, inducing cell apoptosis and necrosis.
Loss of RASSF1A synergizes with deregulated RUNX2 (show RUNX2 Antibodies) signaling in tumorigenesis.
Concomitant with the loss of Rassf1a, the loss of p53 (show TP53 Antibodies) (which causes unrestrained propagation of tetraploids into aneuploid cells) further undermines genomic stability and accelerates tumorigenesis.
Data show that methylation of CCND-2 (show CCND2 Antibodies), p16 (show CDKN2A Antibodies), RAR-beta (show RARB Antibodies) and RASSF-1a was significantly more prevalent in tumor than in normal tissue specimens.
Rassf1A acts as a tumor suppressor gene.
cooperation between inactivation of Rassf1a and Apc (show APC Antibodies) resulting in accelerated intestinal tumourigenesis.
RASSF1A mediates p21Cip1/Waf1 (show CDKN1A Antibodies)-dependent cell cycle arrest and senescence through modulation of the Raf (show RAF1 Antibodies)-MEK (show MDK Antibodies)-ERK (show EPHB2 Antibodies) pathway and inhibition of Akt (show AKT1 Antibodies).
data establish RASSF1A as a novel inhibitor of cardiac hypertrophy by modulating the extracellular regulated kinase 1/2 pathway.
This gene encodes a protein similar to the RAS effector proteins. Loss or altered expression of this gene has been associated with the pathogenesis of a variety of cancers, which suggests the tumor suppressor function of this gene. The inactivation of this gene was found to be correlated with the hypermethylation of its CpG-island promoter region. The encoded protein was found to interact with DNA repair protein XPA. The protein was also shown to inhibit the accumulation of cyclin D1, and thus induce cell cycle arrest. Several alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
Ras association (RalGDS/AF-6) domain family 1
, Ras association (RalGDS/AF-6) domain family member 1
, ras association domain-containing protein 1
, Ras association domain family 1
, cardiac-specific ras association domain family 1 protein
, pancreas-specific ras association domain family 1 protein
, tumor suppressor protein RDA32
, 123F protein
, RASSF1A tumor suppressor
, protein 123F2